European Journal of Biomedical and Pharmaceutical Sciences

MOLECULAR DETECTION OF TYROSINE KINASE INHIBITOR RESISTANT MUTATIONS T3151AND F317L IN CHRONIC MYELOID LEUKEMIA IN SUDAN

*Noah Awad, Aboalgasim Abaas, Nawal Altayeb and Hiba Khalil

ABSTRACT

Background and Objectives: Chronic myeloid leukemia (CML) is disease that differentiated by gene called the bcr-abl fusion gene which produced bcr-abl fusion protein. The detection of tyrosine kinase inhibitor (TKI), imatinib, enhancement the treatment of CML patients, some patients resistant to the Imatinib resulting in increased bcr-abl level. Our general objective is to determine the frequencies and prognostic value of T3151and F317L resistant mutations in Sudanese patients with chronic myeloid leukemia, the specific objectives to generate strategies for improving treatment choices and detect resistant to therapy. Methods: Across-sectional hospital base study conducted from June 2017 to October 2019 at Alneelain University, faculty of Medical Laboratory Sciences, Khartoum, Sudan. All CML patients were diagnosed Positive of Philadelphia chromosome from Hematology oncology at Radio and Isotope Center at Khartoum, Sudan after the approval of study. Patients were included both sexes, Philadelphia chromosome result, bone marrow report, clinical feature, WHO criteria for phases of disease and treatment. Results: Tow patients (2%) were found positive for both T315I mutant gene and F313L mutation and only one patient was positive for T315I mutant gene. Interpretation & conclusions: 3% positive T315I mutation and 2% positive F315L mutation are rare among the African population and very important to discover that. Screenings for bcr-abl mutations test for T315I and F317L mutations in CML patients give a good choice of specific treatment after resistant to Imatinib. We plan for future to investigate CML patients to screening tyrosine domain for other mutations before treatment as strategies.

Keywords: Allele – specific oligonucleotide polymerase chain reaction, Chronic Myeloid Leukemia, Imatinib, Myeloproliferative disease, Resistance.